Pharmacogenetics in Latin American populations: Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders

Drug Metabolism and Drug Interactions

Volumn 27, Issue 1, 2012, Pages 57-60

  Rodeiro, Idania ^a,b,m   Remírez Figueredo, Diadelis ^a,c   García Mesa, Milagros ^d   Dorado, Pedro ^a,e   Llerena, Adrián ^a,e   Moya, Graciela E ^f   Ferrero, Verónica ^f   Tarazona Santos, Eduardo ^g,h   Fiedler, Jenny ⁱ   Herrera, Luisa ⁱ   Rojas Ponce, Romina ^j   Sarmiento Sánchez, Alba P ^k   Borbón Orejuela, Angélica ^k   Barrantes, Ramiro ^l   Jiménez Arce, Gerardo ^l   Céspedes, Carolina ^l   Álvarez, Mayra ⁿ   Pérez, Bárbaro ⁿ   Calzadilla, Luis ^o   Delgado, René ^p   Remirez, Diadelis ^q   Terán, Enrique ^r,s   Heras, Natalia ^s   Beltrán, Leonardo ^s   Hernández, Francisco ^t   Doredo, Pedro ^e   Peñas Lledó, Eva M ^e   Cobaleda, Jesús ^e   González Naranjo, M Eugenia ^e   De Andrés, Fernando ^e   Ortiz López, Rocío ^u   Rojas Martínez, Augusto ^u   Garza Ocañas, Lourdes ^u   Pérez Páramo, Yadira X ^u   López López, Marisol ^v   Ortega Vázquez, Alberto ^v   Alonso Vilatela, Elisa ^w   Monroy Jaramillo, Nancy ^w   Vázquez, Teresa Corona ^w   Yescas Gómez, Petra ^w   Ochoa Morales, Adriana ^w   Sosa Macías, Martha G ^x   Galaviz Hernández, Carlos ^x   Lares, Ismael ^x   Lazalde, Blanca ^x   Ramirez Roa, Ronald ^y   Grazina, Manuela ^z   Estévez Carrizo, Francisco E ^aa   González Vacarezza, Nicolás ^aa   more..

^a Ibero American Network of Pharmacogenetics and Pharmacogenomics (RIBEF)   (Cuba)

^b Centre of Marine Bioproducts (CEBIMAR)   (Cuba)

^c National Centre for State Quality Control of Drugs (CECMED)   (Cuba)

^d National Institute for Angiology and Vascular Surgery   (Cuba)

^e UNIVERSITY OF EXTREMADURA   (Spain)

^f PONTIFICIA UNIVERSIDAD CATÓLICA ARGENTINA   (Argentina)

^g FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^h ASOCIACIÓN BENÉFICA PRISMA   (Peru)

ⁱ UNIVERSITY OF CHILE   (Chile)

^j UNIVERSITY OF CONCEPCIÓN   (Chile)

^k PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^l UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^m Centro de Bioproductos Marinos CEBIMAR   (Cuba)

ⁿ Facultad de Medicina Calixto Garcia   (Cuba)

^o Centro Comunitario de Salud Mental La Habana Vieja   (Cuba)

^p CENTRO DE INVESTIGACIÓN Y DESARROLLO DE MEDICAMENTOS CIDEM   (Cuba)

^q CEMED   (Cuba)

^r UNIVERSIDAD SAN FRANCISCO DE QUITO   (Ecuador)

^s UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

^t UNIVERSIDAD DE GUAYAQUIL   (Ecuador)

^u UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^v UNIVERSIDAD AUTÓNOMA METROPOLITANA   (Mexico)

^w NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^x INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^y en el Jardín botánico ambiental de la UNAN León   (Nicaragua)

^z UNIVERSITY OF COIMBRA   (Portugal)

^aa UNIVERSIDAD DE MONTEVIDEO   (Uruguay)

more..

Author keywords

cytochrome P450; Hispanics; Latin America; pharmacogenetics

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450; DIGOXIN; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; HERBACEOUS AGENT; INDINAVIR; IRINOTECAN; MANGIFERA INDICA EXTRACT; NATURAL PRODUCT; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ARGENTINA; BRAZIL; CARDIOVASCULAR DISEASE; CHILE; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COLOMBIA; CONFERENCE PAPER; COSTA RICA; CUBA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; EATING DISORDER; ECUADOR; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; ENZYME INDUCTION; ETHNICITY; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHY; GERIATRIC PATIENT; HERBAL MEDICINE; HISPANIC; HUMAN; HYPERICUM PERFORATUM; LEGAL ASPECT; MEDICAL SOCIETY; MENTAL DISEASE; NICARAGUA; PERU; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; POPULATION RESEARCH; PORTUGAL; PROTEIN EXPRESSION; RISK BENEFIT ANALYSIS; SOUTH AND CENTRAL AMERICA; SPAIN; SUICIDE; SYMPOSIUM; URUGUAY;

CARDIOVASCULAR DISEASES; HERBAL MEDICINE; HUMANS; LATIN AMERICA; MENTAL DISORDERS; PHARMACOGENETICS;

EID: 84860531136     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2012-0006     Document Type: Conference Paper

References (16)

1. Goodsaid F, Frueh WF. Implementing the US FDA guidance on pharmacogenomic data submissions. Environ Mol Mutagen 2007;48:354-8. (Pubitemid 47011763)
2. Lesko LJ, Woodcock J. Pharmacogenomic-guided drug development: regulatory perspective. Pharmacogenomics J 2002;2: 20-4. (Pubitemid 34982199)
3. Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 2006;7:889-908. (Pubitemid 44446737)
4. Lambert JD, Sang S, Lu AY, Yang CS. Metabolism of dietary polyphenols and possible interactions with drugs. Curr Drug Metab 2008;8:499-507.
5. Galli F. Interactions of polyphenolic compounds with drug disposition and metabolism. Curr Drug Metab 2008;8:830-8.
6. Rodeiro I, Donato MT, Lahoz A, González JA, Laguna A, Castell JV, et al. Modulation of P450 enzymes by Cuban natural products rich in polyphenolic compounds in rat hepatocytes. Chem Biol Interact 2008;172:1-10. (Pubitemid 351284549)
7. Rodeiro I, Donato MT, Lahoz A, Garrido G, Delgado R, Gómez- Lechón MJ. Interactions of polyphenols with the P450 system: possible implications on human therapeutics. Mini Rev Med Chem 2008;8:97-106. (Pubitemid 351320934)
8. Postuła M, Tarchalska-Kryńska B, Filipiak K, Kosior D, Serafin A, Huczek Z, et al. Factors responsible for " aspirin resistance "-can we identify them? Kardiol Pol 2010;68:403-11.
9. Spiewak M, Małek LA, Kostrzewa G, Kisiel B, Serafin A, Filipiak KJ, et al. Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. Kardiol Pol 2009;67:827-34.
10. Kasotakis G, Pipinos II, Lynch TG. Current evidence and clinical implications of aspirin resistance. Vasc Surg 2009;50: 1500-10.
11. Peñas-LLedó EM, Dorado P, Pacheco R, González I, LLerena A. Relation between CYP2D6 genotype, personality, neu-rocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 2009;10:1111-20.
12. Peñas-Lledó EM, Dorado P, Agüera Z, Gratacós M, Estivill X, Fernández-Aranda F, et al. High-risk of lifetime history of suicide attempts among CYP2D6 ultrarapid metabolizers with eating disorders. Mol Psychiatry 2011;16:691-2.
13. Peñas-Lledó EM, Dorado P, Agüera Z, Gratacós M, Estivill X, Fernández-Aranda F, et al. CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics J 2010;Sep 28. Epub ahead of print.
14. Llerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, et al. CYP2D6 genotype and debrisoquine hydroxyla-tion phenotype in Cubans and Nicaraguans. Pharmacogenomics J 2010;Dec 7. Epub ahead of print.
15. Dorado P, Sosa-Macias MG, Peñas-Lledó EM, Alanis-Bañuelos RE, Wong ML, Licinio J, et al. CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics J 2011;11:108-12.
16. Dorado P, Heras N, Machín E, Hernández F, Teran E, Llerena A. CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. Eur J Clin Pharmacol 2011;Nov 15. Epub ahead of print.